Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
9 search results for:

Binimetinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 14-09-2018 | EMA | News | Article
    approvalsWatch

    EMA supports encorafenib plus binimetinib combination

    medwireNews : The EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization be given for the combination of encorafenib and binimetinib in patients with BRAF V600-mutated unresectable or metastatic melanoma.

  2. 23-04-2018 | Melanoma | News | Article

    Encorafenib–binimetinib a new option for BRAF-mutated melanoma

    The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib has favorable efficacy and tolerability relative to either encorafenib or vemurafenib alone in patients with advanced melanoma harboring BRAF mutations, phase III trial findings indicate. Read the accompanying comment by Eva Muñoz Couselo

    Published in:
    Lancet Oncol 2018; Advance online publication
  3. 22-06-2018 | Melanoma | Highlight | Teaser
    medwireNews@ASCO2018

    COLUMBUS OS data favor encorafenib–binimetinib for advanced BRAF-mutated melanoma

    An updated analysis of the phase III COLUMBUS trial adds to the evidence supporting a combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib in patients with advanced BRAF V600-mutant melanoma.

  4. 18-06-2018 | Melanoma | ASCO 2018 | Article
    News in brief

    COLUMBUS OS data favor encorafenib–binimetinib for advanced BRAF-mutated melanoma

    An updated analysis of the phase III COLUMBUS trial adds to the evidence supporting a combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib in patients with advanced BRAF V600-mutant melanoma.

  5. 14-03-2017 | Melanoma | News | Article

    Binimetinib extends NRAS-mutated metastatic melanoma PFS

    Binimetinib could be incorporated into the treatment pathway of patients with advanced melanoma harboring NRAS mutations, say researchers who found a progression-free survival benefit with the MEK inhibitor over dacarbazine.

    Published in:
    Lancet Oncol 2017; Advance online publication
  6. 05-07-2018 | FDA | News | Article
    approvalsWatch

    Encorafenib–binimetinib approved for BRAF-mutated advanced melanoma

    medwireNews : The US FDA has approved the use of encorafenib plus binimetinib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

  7. 21-03-2018 | Targeted therapy | Article

    Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    Dummer R et al.  Lancet Oncol 2018; 19(5): 603-615. doi:10.1016/S1470-2045(18)30142-6

  8. 06-03-2017 | Melanoma | Article

    Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

    Dummer R et al.  Lancet Oncol  2017; 18(4): 435-445. doi:10.1016/S1470-2045(17)30180-8

  9. 23-04-2018 | Article

    Expert comment

    Comment on: Encorafenib–binimetinib a new option for BRAF-mutated melanoma

    Author:
    Eva Muñoz Couselo
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.